psilocybin low-dose / Sansero Life Sci, University of Toronto - LARVOL DELTA

Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications (BioSpace) - "Sansero Life Sciences...announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and how low-dose psilocybin affects mental health conditions such as depression and anxiety. The research agreement between Sansero and the University of Toronto is an important step in expanding the company’s pharmaceutical product development program."

Licensing / partnership • Preclinical • CNS Disorders • Depression • General Anxiety Disorder